Irritant contact dermatitis (ICD) is a multifarious syndrome with numerous clinical presentations and a varied pathophysiology; therefore, its management is not clearly defined and depends on several factors, including clinical phenotype, evolutionary stage, causative factors, and pathophysiology. The management of ICD lies principally in the avoidance of the offending agent(s) and the adoption of appropriate skin care measures. However, in certain circumstances, avoidance protocols are unattainable, and ongoing symptomatic therapy is needed, aimed mainly to mitigate the inflammatory component and its consequences. This chapter will review established preventive and therapeutic measures, including the utilization of non-soap hydrating cleansers, anti-pruritic and antibacterial soaks, therapeutic moisturizers, skin barrier protectants, and anti-inflammatory and immunomodulatory agents such as topical corticosteroids (TCs) and calcineurin inhibitors (TCI). Although TCs are generally used by dermatologists as an ICD treatment, their effectiveness has been questioned both in experimentally induced ICD and in the treatment of patients with ICD. Also, the role of systemic therapy will be discussed. In this context, the short-term use of systemic glucocorticoids should be limited to extensive or severe acute ICD or acute exacerbations of chronic ICD. Special consideration will be given to the treatment of irritant hand dermatitis (HD), principally moderate-to-severe chronic forms, including the use of alitretinoin and immunosuppressants. Finally, the available evidence for some new and promising therapies such as Dupilumab and JAK inhibitors will be reviewed.